Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD). (September 2016) - Wong, N.; Kulikowski, E.; Wasiak, S.; Gilham, D.; Calosing, C.; Laura, T.; Halliday, C.; Johansson, J.; Sweeney, M.